Shreehas Tambe Appointed CEO of Biocon Limited Effective April 2026

Leadership Transition at Biocon Limited

In a significant move set to reshape the future of the biopharmaceutical landscape, Biocon Limited has appointed Shreehas Tambe as CEO and Managing Director, effective April 1, 2026. This strategic leadership transition was approved by the Nomination and Remuneration Committee, as well as the Board of Directors, signaling a new chapter for the company.

Alongside Tambe's appointment, Kedar Upadhye has been named Chief Financial Officer, further solidifying the executive team poised to take Biocon into its next phase of growth. This leadership change comes as Biocon integrates Biocon Biologics Limited completely into its operations, creating a unified and streamlined corporate structure. The new entity is strategically positioned to lead in critical healthcare areas such as diabetes, oncology, obesity, and immunology, supported by a diverse portfolio that includes biosimilars, complex generics, and GLP-1 therapies.

Kiran Mazumdar–Shaw, Executive Chairperson of Biocon Limited, expressed confidence in Shreehas' ability to drive the company forward. "Biocon has continually grown by anticipating patient needs and staying ahead of market trends," she said. "With the integration of our generic and biosimilar activities, we are now crafting a global biopharmaceutical entity with a unique market position. Shreehas has been at the forefront of this transformation, and his leadership will be pivotal as we consolidate our strengths in this competitive industry."

Over his tenure, Shreehas Tambe has played various significant roles, eventually becoming CEO of Biocon Biologics Limited, where he oversaw the company’s ascendancy as one of the world’s top five biosimilars firms, with an estimated valuation of around $5.5 billion as of 2025. His previous experience includes strategic acquisitions and global expansion initiatives which have fortified Biocon's footprint in international markets.

Reflecting on his new role, Tambe stated, "Leading Biocon at such a critical juncture is an immense honor. We are merging our biologics and generics operations to build a pharmaceutical leader on a global scale. Our success is driven by exceptional talent united by a deep commitment to patient needs. As we broaden our portfolio and expand our global presence, I will focus on reinforcing our foundations, consolidating our activities, and accelerating sustainable growth."

Tambe’s career at Biocon began nearly three decades ago, when he joined as a management intern and progressively moved up the ranks through leadership positions that have been integral to the company’s global business expansion. Under his leadership, Biocon Biologics emerged as a fully integrated biosimilars company, streamlining processes from lab to patient.

In his past roles, Shreehas has demonstrated excellence in overseeing global insulin business expansions, notably establishing the largest integrated insulin facility in Asia, located in Malaysia. He is not only known for his leadership skills but also for his innovative contributions, holding over 60 patents that reflect his dedication to advancing biopharmaceutical research and development.

He holds a postgraduate degree in Bioprocessing Technology from the Institute of Chemical Technology in Mumbai and has received several industry accolades, including the ET Edge India Impactful CEO Award in 2025 and the BW Pharma World Pharma Leadership Award. His influence extends beyond corporate achievements; he has represented the Indian biopharmaceutical sector on international platforms, contributing to vital initiatives such as the Production Linked Incentive scheme and promoting research and innovation in the pharma MedTech sector.

As Shreehas Tambe steps into this new leadership role, he aims to fortify Biocon’s global standing as a leader in addressing pressing healthcare needs. With a portfolio that includes a wide array of biosimilars, insulins, generics, and GLP-1 peptides, Biocon is well-positioned to make significant contributions to the healthcare landscape globally.

About Biocon Limited

Biocon Limited is a global biopharmaceutical company based in Bengaluru, India, dedicated to delivering transformative and affordable medicines to patients around the world. With a focus on chronic and non-communicable diseases, Biocon specializes in biosimilars and generics across multiple geographies. The company aims to address critical unmet medical needs, including in areas such as diabetes, oncology, obesity, and immunology. Biocon has achieved several key milestones that have shaped the global biosimilars market, having launched 12 biosimilars and over 30 generic formulations worldwide.